Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
birch pollen-galactomannan conjugate
- Development stage
- Unknown
- Lead developer
- WAKO FILTER TECHNOLOGY
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Birch pollen-galactomannan conjugate is an investigational allergen immunotherapy (AIT) developed for the treatment of pollen-food allergy syndrome (PFAS) and oral allergy syndrome (OAS) associated with birch pollinosis. The therapeutic consists of birch pollen allergens, primarily the major allergen Bet v 1, covalently linked to galactomannan, a polysaccharide derived from sources such as guar gum. This conjugation strategy is designed to reduce the allergen's IgE-binding capacity, thereby minimizing the risk of systemic allergic reactions (anaphylaxis) during administration, while preserving the ability to stimulate T-cell responses and induce immunological tolerance. The primary clinical goal is to increase the threshold for allergic reactions to cross-reactive foods, such as raw apples, in patients sensitized to birch pollen.
- Other names
- birch pollen-galactomannan conjugate
02
Targets
Bet v 1
Beyond the preview
Go deeper on birch pollen-galactomannan conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on birch pollen-galactomannan conjugate.